In This Issue: Drug Topics April 2024

A higher patient-rated therapeutic alliance was associated with improvements in depression outcomes up to 1 year after treatment.

Digital therapeutics are positioned as front-runners in the increasingly digital future of health care.

With an unprecedented number of Americans in need of mental health care, what role should pharmacists play when it comes to screenings?

In the United States, 12 million adults suffer from co-occurring chronic pain and anxiety or depression. Erasing stigmas, educating patients, and tailoring interventions can help to improve outcomes.

After a long hiatus, research in psychedelic medicine is progressing rapidly. With the potential approval of MDMA in the near future, what role will pharmacists play in integrating these new therapies into treatment plans?

Vistagen has enrolled the first participant in the PALISADE-3 phase 3 trial of fasedienol for the treatment of social anxiety disorder.